Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA)
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA)
Authors
Keywords
Endometrial cancer, Doxorubicin, Palliative chemotherapy
Journal
MEDICAL ONCOLOGY
Volume 35, Issue 3, Pages -
Publisher
Springer Nature
Online
2018-01-31
DOI
10.1007/s12032-018-1086-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-Line Therapy for Endometrial Cancer: The Need for Better Options
- (2015) Gini F. Fleming JOURNAL OF CLINICAL ONCOLOGY
- Uterine Sarcoma, Version 1.2016
- (2015) Wui-Jin Koh et al. Journal of the National Comprehensive Cancer Network
- Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
- (2013) I Ray-Coquard et al. BRITISH JOURNAL OF CANCER
- Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study
- (2013) Shoji Nagao et al. GYNECOLOGIC ONCOLOGY
- Treatment of Advanced or Recurrent Endometrial Carcinoma With Doxorubicin in Patients Progressing After Paclitaxel/Carboplatin
- (2013) Vicky Makker et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2011) N. Colombo et al. ANNALS OF ONCOLOGY
- Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
- (2011) Amit M. Oza et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study
- (2011) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends
- (2011) Carien L. Creutzberg et al. Current Oncology Reports
- Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin
- (2010) Yutaka Ueda et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents
- (2010) K. M. Moxley et al. ONCOLOGIST
- Node-positive adenocarcinoma of the endometrium: Outcome and patterns of recurrence with and without external beam irradiation
- (2009) Ann H. Klopp et al. GYNECOLOGIC ONCOLOGY
- Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P
- (2009) Don S. Dizon et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started